Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by RA Capital Management L.P.

RA Capital Management L.P. cut its stake in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 56.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 336,843 shares of the biopharmaceutical company's stock after selling 429,991 shares during the quarter. RA Capital Management L.P. owned about 0.51% of Regulus Therapeutics worth $532,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in RGLS. State Street Corp grew its position in Regulus Therapeutics by 3.5% during the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company's stock worth $1,572,000 after purchasing an additional 33,496 shares during the period. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at about $46,000. Barclays PLC raised its holdings in Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock worth $132,000 after purchasing an additional 62,549 shares during the period. JPMorgan Chase & Co. grew its holdings in Regulus Therapeutics by 193.4% in the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 52,059 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Regulus Therapeutics by 20.5% in the 4th quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock valued at $185,000 after acquiring an additional 19,900 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Stock Up 0.1 %

NASDAQ RGLS traded up $0.01 during trading hours on Tuesday, hitting $7.86. 678,438 shares of the company were exchanged, compared to its average volume of 871,481. Regulus Therapeutics Inc. has a 52-week low of $0.83 and a 52-week high of $8.20. The firm has a market cap of $520.34 million, a price-to-earnings ratio of -7.34 and a beta of 0.49. The company has a 50 day moving average of $2.24 and a two-hundred day moving average of $1.71.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) EPS for the quarter, meeting analysts' consensus estimates of ($0.20). During the same quarter in the previous year, the company earned ($0.40) earnings per share. On average, equities research analysts predict that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Jones Trading reiterated a "hold" rating and issued a $7.00 target price (down previously from $8.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Canaccord Genuity Group reaffirmed a "hold" rating and set a $11.00 target price (down previously from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Leerink Partnrs cut shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Leerink Partners restated a "market perform" rating and issued a $7.00 target price on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and set a $9.00 price target on shares of Regulus Therapeutics in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $8.50.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.